NEWLINK GENETICS CORP Contracts & Agreements

Agreement and Plan of Merger, by and among Double Point Ventures LLC, DPV Parent, Inc., DPV MergerSub, Inc. and Lumos Pharma, Inc., dated October 22, 2024 (Filed With SEC on October 23, 2024)

Form of Contingent Value Rights Agreement, by and between DPV Parent, Inc. and the Rights Agent (Filed With SEC on October 23, 2024)

Form of Tender and Support Agreement (Filed With SEC on October 23, 2024)

Clinical Trial Funding Agreement, by and among Double Point Ventures LLC and Lumos Pharma, Inc., dated October 22, 2024 (including the form of Note with respect thereto) (Filed With SEC on October 23, 2024)

Description of Securities (Filed With SEC on March 11, 2022)

Form of Indemnity Agreement by and between the Registrant and its directors and officers (Filed With SEC on March 11, 2022)

Employment Agreement, dated August 3, 2021, by and between the Registrant and Dr. David Karp (Filed With SEC on November 5, 2021)

Amendment No. 1, dated June 30, 2021, to Employment Agreement by and between the Registrant and Lori Lawley (Filed With SEC on August 6, 2021)

Amendment No. 1, dated August 4, 2021, to Employment Agreement by and between the Registrant and John McKew (Filed With SEC on August 6, 2021)

Description of Securities (Filed With SEC on March 9, 2021)

Form of Indemnity Agreement by and between the Registrant and its directors and officers (Filed With SEC on March 9, 2021)

Controlled Equity Offering (Filed With SEC on December 30, 2020)

PRV Transfer Agreement, dated as of July 27, 2020, by and between the Registrant and Merck, Sharp & Dohme Corp (Filed With SEC on August 14, 2020)

Amendment No. 1 as of August 12, 2020 to Lumos Merck Agreement with Merck (Filed With SEC on August 14, 2020)

License Agreement by and between Merck Sharp & Dohme Corp. and Ammonett Pharma LLC, effective as of October 22, 2013 (Filed With SEC on June 1, 2020)

Asset Purchase Agreement by and among Lumos Pharma, Inc., Ammonett Pharma LLC, and each of certain individuals listed therein, dated as of July 26, 2018 (Filed With SEC on June 1, 2020)

Employment Agreement, dated as of March 27, 2020, by and between the Registrant and Richard Hawkins (Filed With SEC on April 2, 2020)

Employment Agreement, dated as of March 27, 2020, by and between the Registrant and John McKew (Filed With SEC on April 2, 2020)

Form of Common Stock Certificate (Filed With SEC on March 18, 2020)

Lumos Pharma, Inc. 2012 Equity Incentive Plan (Filed With SEC on March 18, 2020)

2012 Equity Incentive Plan Form of Incentive Stock Option Grant Notice (Filed With SEC on March 18, 2020)

Lumos Pharma, Inc. 2016 Stock Plan (Filed With SEC on March 18, 2020)

2016 Form of Stock Option Grant Notice (Filed With SEC on March 18, 2020)

Description of Securities (Filed With SEC on March 3, 2020)

Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated November 19, 2019, by and among NewLink Genetics Corporation, Cyclone Merger Sub, Inc. and Lumos Pharma,... (Filed With SEC on November 20, 2019)

Separation Agreement by and between the Registrant and Charles J. Link, Jr. dated August 3, 2019 (Filed With SEC on November 6, 2019)

Form of Support Agreement, by and between NewLink Genetics Corporation and its directors and officers and by and between NewLink Genetics Corporation and Stine Seed Farm, Inc (Filed With SEC on September 30, 2019)

Form of Lock-Up Agreement (Filed With SEC on September 30, 2019)

Transition Agreement, by and between NewLink Genetics Corporation and Nicholas Vahanian, dated September 27, 2019 (Filed With SEC on September 30, 2019)

Employment Agreement, by and between NewLink Genetics Corporation and Carl Langren, dated September 30, 2019 (Filed With SEC on September 30, 2019)

Employment Agreement, by and between NewLink Genetics Corporation and Eugene Kennedy, dated September 30, 2019 (Filed With SEC on September 30, 2019)

Employment Agreement, by and between NewLink Genetics Corporation and Brad Powers, dated September 30, 2019 (Filed With SEC on September 30, 2019)

Employment Agreement, by and between NewLink Genetics Corporation and Lori Lawley, dated September 30, 2019 (Filed With SEC on September 30, 2019)

Agreement and Plan of Merger and Reorganization, dated September 30, 2019, by and among NewLink Genetics Corporation, Cyclone Merger Sub, Inc. and Lumos Pharma, Inc (Filed With SEC on September 30, 2019)

Amended and Restated 2009 Equity Incentive Plan (Filed With SEC on August 8, 2019)

License Agreement dated September 13, 2005 by and between the Registrant and Medical College of Georgia Research Institute, Inc (Filed With SEC on May 8, 2019)

Amendment to License Agreement dated April 27, 2006 by and between the Registrant and Medical College of Georgia Research Institute, Inc (Filed With SEC on May 8, 2019)

Amendment to License Agreement dated February 13, 2007 by and between the Registrant and Medical College of Georgia Research Institute, Inc (Filed With SEC on May 8, 2019)

Amendment dated March 28, 2006 to the License Agreement by and between the Company and Georgia Regents Research Institute, Inc., formerly known as Medical College of Georgia... (Filed With SEC on May 8, 2019)

Amendment to License Agreement dated July 10, 2014 by and between the Registrant and Medical College of Georgia Research Institute, Inc (Filed With SEC on May 8, 2019)

Amendment to License and Collaboration Agreement dated (Filed With SEC on March 5, 2019)

Amendment to the (Filed With SEC on March 5, 2019)

2019 Equity Awards (Filed With SEC on March 5, 2019)

Amendment No. 3 to License and Collaboration Agreement by and between the Registrant and Merck Sharp & Dohme Corp., dated October 9, 2018 (Filed With SEC on November 2, 2018)

Separation and Release Agreement, dated as of July 26, 2018, between the Registrant and John B. Jack Henneman III (Filed With SEC on November 2, 2018)

Separation and Release Agreement, dated July 26, 2018, between the Registrant and Brian Wiley (Filed With SEC on November 2, 2018)

Employment Agreement, dated July 26, 2018, between the Registrant and Carl W. Langren (Filed With SEC on November 2, 2018)

Employment Agreement, dated July 26, 2018, between the Registrant and Lori Lawley (Filed With SEC on November 2, 2018)

Amendment to License and Collaboration Agreement by and between Merck Sharp & Dohme Corp., dated May 10, 2018 (Filed With SEC on August 6, 2018)

2018 Equity Awards (Filed With SEC on March 15, 2018)

Controlled Equity OfferingSM Sales Agreement, dated March 12, 2018, by and between NewLink Genetics Corporation and Cantor Fitzgerald & Co (Filed With SEC on March 13, 2018)

Amendment to License and Collaboration Agreement dated December 5, 2017 by and among the Company, BioProtection Systems Corporation and Merck Sharp & Dohme Corp (Filed With SEC on March 5, 2018)

Amended and Restated License Agreement by and between BioProtection Systems Corporation and Her Majesty the Queen in Right of Canada, as represented by the Minister of Health,... (Filed With SEC on March 5, 2018)

Underwriting Agreement, dated October 3, 2017 (Filed With SEC on October 4, 2017)

ASSET PURCHASE AGREEMENT (Filed With SEC on March 20, 2017)

LICENSE AGREEMENT (Filed With SEC on March 20, 2017)

2016 Bonus Awards and Supplemental Bonus AwardsName and Title2016 Annual SalaryGoal Bonus at 100%Bonus AwardedBonus AmountSupplemental Bonus AmountCharles J. Link, Jr.,... (Filed With SEC on January 5, 2017)

NewLink Genetics Corporation 2010 Non-Employee Directors Stock Award Plan Adopted by the Board of Directors: October 29, 2010 Approved by the Stockholders: January 7, 2011 Amended... (Filed With SEC on November 8, 2016)

[*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to... (Filed With SEC on August 5, 2016)

NewLink Genetics Corporation 2010 Non-Employee Directors Stock Award Plan Adopted by the Board of Directors: October 29, 2010 Approved by the Stockholders: January 7, 2011 Amended... (Filed With SEC on August 5, 2016)

SIXTH AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on April 29, 2016)

LICENSE AGREEMENT (Filed With SEC on April 29, 2016)

RESEARCH SERVICES AGREEMENT (Filed With SEC on April 29, 2016)

Memorandum of Agreement (Filed With SEC on February 29, 2016)

FIRST AMENDED AND RESTATED CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation (Filed With SEC on February 29, 2016)

2015 Bonus AwardsName and TitleBonus Target*Goal Percentage AchievedBonus Target Achieved*2015 SalaryTotal Cash Bonus AwardedCharles J. Link, Jr.,... (Filed With SEC on January 7, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on January 7, 2016)

NewLink Genetics Corporation 2010 Non-Employee Directors Stock Award Plan Adopted by the Board of Directors: October 29, 2010 Approved by the Stockholders: January 7, 2011 Amended... (Filed With SEC on August 6, 2015)

NewLink Genetics Corporation 2010 Non-Employee Director Stock Award Plan, as Amended Restricted Stock Unit Award Agreement (Filed With SEC on August 6, 2015)

Exhibit A EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS, NON-COMPETITION, AND NON-SOLICITATION AGREEMENT (Filed With SEC on August 6, 2015)

FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN NEWLINK GENETICS CORPORATION, NEWLINK GLOBAL, GENENTECH, INC. AND F. HOFFMANN-LA ROCHE LTD OF OCTOBER 16,... (Filed With SEC on May 11, 2015)

LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on March 16, 2015)

Sq. Ft.Sq. Ft.MonthlyMonthlyAnnualAnnualBaseOperatingBaseOperatingBaseOperatingTermRentsRentsRentsRentsRentsRents11/1/2014-10/31/2015$12.75Actual$3,343.69Actual$40,124.28Actual (Filed With SEC on March 16, 2015)

Sq. Ft.Sq. Ft.MonthlyMonthlyAnnualAnnualBaseOperatingBaseOperatingBaseOperatingTermRentsRentsRentsRentsRentsRents2/1/2015-1/31/2018$10.50Actual$5,923.75Actual$71,085.00Actual (Filed With SEC on March 16, 2015)

Memorandum of Agreement (Filed With SEC on March 16, 2015)

2014 Bonus AwardsName and TitleBonus Target*Goal Percentage AchievedBonus Target Achieved*2014 SalaryTotal Cash Bonus AwardedCharles J. Link, Jr.,... (Filed With SEC on January 6, 2015)

2015 Salaries, Bonus Targets and Equity AwardsName and Title2015 SalaryBonus Target*Stock OptionsRestricted Stock Unit AwardsCharles J. Link, Jr., M.D.$640,70060%143,000 45,000... (Filed With SEC on January 6, 2015)

License and Collaboration Agreement by and between NewLink Genetics Corporation and NewLink Global and Genentech, Inc. and F. Hoffmann-La Roche Ltd October 16, 2014 (Filed With SEC on November 10, 2014)

Amendment to Development and Manufacturing Terms and Conditions (Filed With SEC on November 10, 2014)

LICENSE AGREEMENT AMENDMENT (Filed With SEC on November 10, 2014)

AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on November 10, 2014)

Exhibit A EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS, NON-COMPETITION, AND NON-SOLICITATION AGREEMENT (Filed With SEC on October 1, 2014)

CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation (Filed With SEC on August 5, 2014)

Development and Process Transfer Program Leading to Commercial Manufacturing for algenpantucel-L HyperAcute" Pancreas Technical Transfer, Verification / Process Development,... (Filed With SEC on August 5, 2014)

NEWLINK GENETICS CORPORATION 2010 NON-EMPLOYEE DIRECTORS STOCK AWARD PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 29, 2010 APPROVED BY THE STOCKHOLDERS: JANUARY 7, 2011 AMENDED... (Filed With SEC on August 5, 2014)

NEWLINK GENETICS CORPORATION 2010 NON-EMPLOYEE DIRECTOR STOCK AWARD PLAN, AS AMENDED RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on August 5, 2014)

NEWLINK GENETICS CORPORATION RESTRICTED STOCK UNIT GRANT NOTICE (2010 NON-EMPLOYEE DIRECTOR STOCK AWARD PLAN, AS AMENDED) (Filed With SEC on August 5, 2014)

NEWLINK GENETICS CORPORATION 2009 EQUITY INCENTIVE PLAN, AS AMENDED RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on August 5, 2014)

NEWLINK GENETICS CORPORATION RESTRICTED STOCK UNIT GRANT NOTICE (2009 EQUITY INCENTIVE PLAN, AS AMENDED) [FOUR YEAR ANNUAL VESTING] (Filed With SEC on August 5, 2014)

NEWLINK GENETICS CORPORATION RESTRICTED STOCK UNIT GRANT NOTICE (2009 EQUITY INCENTIVE PLAN, AS AMENDED) [IMMEDIATELY VESTED] (Filed With SEC on August 5, 2014)

Memorandum of Agreement (Filed With SEC on March 12, 2014)

AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on March 12, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on March 12, 2014)

2013 Bonus AwardsName and TitleBonus Target*Goal Percentage AchievedBonus Target Achieved*2013 SalaryTotal Cash Bonus AwardedRestricted Stock Unit AwardsCharles J. Link, Jr.,... (Filed With SEC on January 8, 2014)

2014 Salaries, Bonus Targets and Equity AwardsName and Title2014 SalaryBonus Target*Total Cash Bonus TargetStock OptionsRestricted Stock Unit AwardsCharles J. Link, Jr.,... (Filed With SEC on January 8, 2014)

LICENSE AGREEMENT AMENDMENT (Filed With SEC on November 12, 2013)

NewLink Genetics Corporation Up to $60,000,000 of Shares of Common Stock (par value $0.01 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on September 5, 2013)

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on August 14, 2013)

CONSENSUSDOCS 415 STANDARD DESIGN-BUILD AGREEMENT AND GENERAL CONDITIONS BETWEEN OWNER AND DESIGN-BUILDER (Where the Basis of Payment is a Lump Sum Based on an Owner's Program... (Filed With SEC on August 8, 2013)

Memorandum of Agreement (Filed With SEC on August 8, 2013)

NEWLINK GENETICS CORPORATION 2010 NON-EMPLOYEE DIRECTORS STOCK AWARD PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 29, 2010 APPROVED BY THE STOCKHOLDERS: JANUARY 7, 2011 AMENDED... (Filed With SEC on May 14, 2013)

NEWLINK GENETICS CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 29, 2010 APPROVED BY THE STOCKHOLDERS: JANUARY 7, 2011 AMENDED BY THE... (Filed With SEC on May 14, 2013)

Memorandum of Agreement (Filed With SEC on May 8, 2013)

2013 Target Bonus Awards 2013TargetBonusNameandTitlePercentage of 2013 Base SalaryTotal Target BonusCharles J. Link, Jr.,M.D.Chairman of the Board and Chief Executive and... (Filed With SEC on April 5, 2013)

Memorandum of Agreement (Filed With SEC on March 15, 2013)

4,000,000 Shares NewLink Genetics Corporation UNDERWRITING AGREEMENT (Filed With SEC on January 31, 2013)

NEWLINK GENETICS CORPORATION 2010 NON-EMPLOYEE DIRECTORS STOCK AWARD PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 29, 2010 APPROVED BY THE STOCKHOLDERS: JANUARY 7, 2011 AMENDED... (Filed With SEC on January 18, 2013)

2012 Bonus AwardsName and TitlePossible PercentageGoal Percentage AchievedBonus Percentage Achieved2012 SalaryTotal Bonus AwardedCharles J. Link, Jr.,... (Filed With SEC on December 21, 2012)

2013 Salary and Target BonusName and Title2013 SalaryPercentage of 2013 Base SalaryTotal Target BonusCharles J. Link, Jr., M.D.$540,80055%$297,440Chairman of the Board and Chief... (Filed With SEC on November 7, 2012)

NEWLINK GENETICS CORPORATION AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on May 10, 2012)

PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH (Filed With SEC on May 10, 2012)

NewLink Genetics receives notice of allowance from USPTO for new patent broadly covering its D-1MT IDO pathway inhibitor (Filed With SEC on April 25, 2012)

NewLink Genetics receives notice of allowance from the Japan Patent Office for new patent broadly covering its HyperAcute cancer immunotherapy products (Filed With SEC on April 17, 2012)

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (Filed With SEC on March 30, 2012)

CERTIFICATION (Filed With SEC on March 30, 2012)

EXHIBIT 32.1 CERTIFICATION (Filed With SEC on March 30, 2012)

NewLink Genetics Corporation Reports Fourth Quarter and Full-Year 2011 Financial Results Conference call scheduled for 5:00 pm EDT March 29, 2012 (Filed With SEC on March 29, 2012)

SETTLEMENT AGREEMENT (Filed With SEC on March 28, 2012)

2012 Target Bonus Awards 2012TargetBonusNameandTitlePercentage of 2012 Base SalaryTotal Target BonusCharles J. Link, Jr.,M.D.Chairman of the Board and Chief Executive and... (Filed With SEC on March 28, 2012)

Policy on Stockholder Recommendations of Director Nominees (Filed With SEC on March 12, 2012)

Memorandum of Agreement (Filed With SEC on November 18, 2011)

NEWLINK GENETICS CORPORATION [ ],000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on November 8, 2011)

LOCK-UP AGREEMENT NewLink Genetics Corporation Public Offering of Common Stock (Filed With SEC on November 8, 2011)

NEWLINK GENETICS CORPORATION 2010 NON-EMPLOYEE DIRECTORS STOCK AWARD PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 29, 2010; AMENDED JULY 1, 2011 APPROVED BY THE STOCKHOLDERS:... (Filed With SEC on November 8, 2011)

INDEMNITY AGREEMENT (Filed With SEC on November 8, 2011)

LICENSE AGREEMENT BETTWEEN LANKENAU INSTITUTE FOR MEDICAL RESEARCH AND NEWLINK GENETICS CORPORATION (Filed With SEC on November 8, 2011)

AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on November 8, 2011)

AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on November 8, 2011)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 8, 2011)

LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA and NEWLINK GENETICS CORPORATION Table of Contents (Filed With SEC on November 8, 2011)

LICENSE AGREEMENT BETWEEN NEWLINK GENETICS AND DREXEL UNIVERSITY EFFECTIVE AS OF OCTOBER 13th, 2004 (Filed With SEC on November 8, 2011)

LICENSE AGREEMENT BETWEEN CENTRAL IOWA HEALTH SYSTEM AND NEWLINK GENETICS CORPORATION (Filed With SEC on November 8, 2011)

Appendix A Letter of Intent Research Plan (Filed With SEC on November 8, 2011)

WITNESSETH (Filed With SEC on November 8, 2011)

LICENSE AGREEMENT AMENDMENT (Filed With SEC on November 8, 2011)

EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and BIOPROTECTION SYSTEMS CORPORATION for Recombinant Yellow Fever Virus as a Vaccine Vector [*] (Filed With SEC on November 8, 2011)

HER MAJESTY THE QUEEN IN RIGHT OF CANADA, as represented by the Minister of Health, acting through the Public Health Agency of Canada (Canada) (Filed With SEC on November 8, 2011)

Memorandum of Agreement (Filed With SEC on October 26, 2011)

LICENSE AGREEMENT BETTWEEN LANKENAU INSTITUTE FOR MEDICAL RESEARCH AND NEWLINK GENETICS CORPORATION (Filed With SEC on October 4, 2011)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on October 4, 2011)

LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA and NEWLINK GENETICS CORPORATION Table of Contents (Filed With SEC on October 4, 2011)

LICENSE AGREEMENT BETWEEN NEWLINK GENETICS AND DREXEL UNIVERSITY EFFECTIVE AS OF OCTOBER 13th, 2004 (Filed With SEC on October 4, 2011)

LICENSE AGREEMENT BETWEEN CENTRAL IOWA HEALTH SYSTEM AND NEWLINK GENETICS CORPORATION (Filed With SEC on October 4, 2011)

Appendix A Letter of Intent Research Plan (Filed With SEC on October 4, 2011)

AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent (Filed With SEC on October 4, 2011)

AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent (Filed With SEC on October 4, 2011)

AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)

AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)

AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)

AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)

AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)

WITNESSETH (Filed With SEC on October 4, 2011)

LICENSE AGREEMENT AMENDMENT (Filed With SEC on October 4, 2011)

EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and BIOPROTECTION SYSTEMS CORPORATION for Recombinant Yellow Fever Virus as a Vaccine Vector [*] (Filed With SEC on October 4, 2011)

HER MAJESTY THE QUEEN IN RIGHT OF CANADA, as represented by the Minister of Health, acting through the Public Health Agency of Canada (Canada) (Filed With SEC on October 4, 2011)

AMENDMENT #8 To Letter of Intent for Proposed CRADA #02166 Preclinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent (Filed With SEC on October 4, 2011)

Issue Date: 03/24/2011 (Filed With SEC on October 4, 2011)

CONTRACT AMENDMENT (Filed With SEC on September 14, 2011)

PROMISSORY NOTE (Filed With SEC on February 28, 2011)

G.R. Neumann (Filed With SEC on February 28, 2011)

AMENDMENT AGREEMENT (Filed With SEC on February 28, 2011)

LICENSE AGREEMENT BETWEEN CENTRAL IOWA HEALTH SYSTEM AND NEWLINK GENETICS CORPORATION (Filed With SEC on February 28, 2011)

Appendix A Letter of Intent Research Plan (Filed With SEC on February 28, 2011)

AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on February 28, 2011)

DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER (Filed With SEC on February 28, 2011)

UNIT (Filed With SEC on February 28, 2011)

SUPPLIES/SERVICES (Filed With SEC on February 28, 2011)

DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER RESEARCH TRIANGLE PARK DIVISION P.O. BOX 12211 RESEARCH TRIANGLE PARK, NORTH... (Filed With SEC on February 28, 2011)

Notice of Award (Filed With SEC on February 28, 2011)

NEWLINK GENETICS CORPORATION 2000 EQUITY INCENTIVE PLAN Adopted bythe Board: March 2, 2000; Amended August 30, 2001 Approved By Stockholders April 10, 2000 and December 12, 2001... (Filed With SEC on December 21, 2010)

NEWLINK GENETICS CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OFDIRECTORS: OCTOBER 29, 2010 APPROVED BY THE STOCKHOLDERS: , 2010 (Filed With SEC on December 21, 2010)

NEWLINK GENETICS CORPORATION 2010 NON-EMPLOYEE DIRECTORS STOCK AWARD PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 29, 2010 APPROVED BY THE STOCKHOLDERS: ,2010 (Filed With SEC on December 21, 2010)

EMPLOYMENT AGREEMENT (Filed With SEC on December 21, 2010)

NEWLINKGENETICS EMPLOYEEPROPRIETARY INFORMATION, INVENTIONS, NON-COMPETITION, AND NON-SOLICITATION AGREEMENT (Filed With SEC on December 21, 2010)

LICENSE AGREEMENT BETTWEENLANKENAU INSTITUTE FOR MEDICAL RESEARCH AND NEWLINK GENETICS CORPORATION (Filed With SEC on December 21, 2010)

FIRST AMENDMENT TO LICENSEAGREEMENT BETWEEN LANKENAU INSTITUTE FOR MEDICAL RESEARCH AND NEWLINK GENETICS CORPORATION DATED JULY 7, 2005 (Filed With SEC on December 21, 2010)

SECOND AMENDMENT TO LICENSEAGREEMENT BETWEEN LANKENAU INSTITUTE FOR MEDICAL RESEARCH AND NEWLINK GENETICS CORPORATION DATED JULY 7, 2005 (Filed With SEC on December 21, 2010)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on December 21, 2010)

LICENSE AGREEMENT Between: THEUNIVERSITY OF BRITISH COLUMBIA and NEWLINK GENETICS CORPORATION Table of Contents (Filed With SEC on December 21, 2010)

LICENSE AGREEMENT BETWEEN NEWLINK GENETICS AND DREXEL UNIVERSITY EFFECTIVE AS OF OCTOBER 13th, 2004 (Filed With SEC on December 21, 2010)

LICENSE AGREEMENT BETWEEN CENTRALIOWA HEALTH SYSTEM AND NEWLINK GENETICS CORPORATION (Filed With SEC on December 21, 2010)

Cooperative Research and Development Agreement (CRADA #1901) [*] NCI Principal Investigator John C. Morris, M.D. Metabolism Branch, CCR, NCI Collaborator PrincipalInvestigator... (Filed With SEC on December 21, 2010)

AMENDMENT #1 COOPERATIVE RESEARCH ANDDEVELOPMENT AGREEMENT # 1901 [*] (Filed With SEC on December 21, 2010)

AMENDMENT #2 COOPERATIVE RESEARCH ANDDEVELOPMENT AGREEMENT # 1901 [*] (Filed With SEC on December 21, 2010)

Appendix A Letter of Intent Research Plan (Filed With SEC on December 21, 2010)

AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)

AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)

AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)

AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)

AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)

AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)

WITNESSETH (Filed With SEC on December 21, 2010)

LICENSE AGREEMENT AMENDMENT (Filed With SEC on December 21, 2010)

RESEARCH AGREEMENT (Filed With SEC on December 21, 2010)

AGREEMENT AMENDMENT First Amendment to Agreement Between NewLink Genetics Corporation and Medical College of Georgia Research Institute, Inc. (Filed With SEC on December 21, 2010)

AGREEMENT AMENDMENT Second Amendment to Agreement Between NewLink Genetics Corporation and Medical College of Georgia Research Institute, Inc. (Filed With SEC on December 21, 2010)

RESEARCH AGREEMENT (Filed With SEC on December 21, 2010)

PROMISSORY NOTE (Filed With SEC on December 21, 2010)

ECONOMIC DEVELOPMENT COMMUNITY INVESTMENT FUND PROGRAM FORGIVABLE LOAN AGREEMENT (NewLink Genetics Corporation) ARTICLE 1.0 GENERAL (Filed With SEC on December 21, 2010)

$6,000,000 IOWA VALUES FUND (IVF) CONTRACT BY AND BETWEEN NEWLINK GENETICS CORPORATION AND THE IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT DATED AS OF MARCH 18, 2005 (Filed With SEC on December 21, 2010)

CONTRACT AMENDMENT BUSINESS: NewLink Genetics Corporation MASTER CONTRACT #: 04-IVF-019 AMENDMENT #: One EFFECTIVE DATE: August 19, 2010 (Filed With SEC on December 21, 2010)

Category

Industry

Companies

Contracts

NEWLINK GENETICS CORP Contracts & Agreements